Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRibute-PN trial of AG10 in symptomatic transthyretin amyloid polyneuropathy
NL-OMON49272Phase 3Active, not recruiting
- Sponsor
- Eidos Therapeutics
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial amyloid polyneuropathy (FAP) comparing AG10 with Placebo (2 arms). Primary endpoint: Change from baseline to Month 18 in Modified Neuropathy Impairment Score + 7. Started Dec 2020; status: active, not recruiting.
02
Drugs
acoramidis
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on NL-OMON49272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49272.